Next Article in Journal
Wearable Fixation Device for a Magnetically Controllable Therapeutic Agent Carrier: Application to Cartilage Repair
Next Article in Special Issue
Nucleic Acid Hybrids as Advanced Antibacterial Nanocarriers
Previous Article in Journal
In Vivo Assessment of Thermosensitive Liposomes for the Treatment of Port Wine Stains by Antifibrinolytic Site-Specific Pharmaco-Laser Therapy
Previous Article in Special Issue
Photoactivatable Surface-Functionalized Diatom Microalgae for Colorectal Cancer Targeted Delivery and Enhanced Cytotoxicity of Anticancer Complexes
Open AccessReview

Recent Advances and Impact of Chemotherapeutic and Antiangiogenic Nanoformulations for Combination Cancer Therapy

1
Pharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Åbo Akademi University, 20520 Turku, Finland
2
Bioscience Department, Sygnature Discovery, Bio City, Pennyfoot St, Nottingham NG1 1GR, UK
3
Turku Bioscience Center, University of Turku and Åbo Akademi University, 20520 Turku, Finland
*
Authors to whom correspondence should be addressed.
Pharmaceutics 2020, 12(6), 592; https://doi.org/10.3390/pharmaceutics12060592
Received: 29 May 2020 / Revised: 17 June 2020 / Accepted: 18 June 2020 / Published: 25 June 2020
(This article belongs to the Special Issue Hybrid Multifunctional Drug Delivery Systems)
Traditional chemotherapy, along with antiangiogenesis drugs (combination cancer therapy), has shown reduced tumor recurrence and improved antitumor effects, as tumor growth and metastasis are often dependent on tumor vascularization. However, the effect of combination chemotherapy, including synergism and additive and even antagonism effects, depends on drug combinations in an optimized ratio. Hence, nanoformulations are ideal, demonstrating a great potential for the combination therapy of chemo-antiangiogenesis for cancer. The rationale for designing various nanocarriers for combination therapy is derived from organic (polymer, lipid), inorganic, or hybrid materials. In particular, hybrid nanocarriers that consist of more than one material construct provide flexibility for different modes of entrapment within the same carrier—e.g., physical adsorption, encapsulation, and chemical conjugation strategies. These multifunctional nanocarriers can thus be used to co-deliver chemo- and antiangiogenesis drugs with tunable drug release at target sites. Hence, this review attempts to survey the most recent advances in nanoformulations and their impact on cancer treatment in a combined regimen—i.e., conventional cytotoxic and antiangiogenesis agents. The mechanisms and site-specific co-delivery strategies are also discussed herein, along with future prospects. View Full-Text
Keywords: anticancer; antiangiogenic agents; nanoformulations; combination cancer therapy anticancer; antiangiogenic agents; nanoformulations; combination cancer therapy
Show Figures

Figure 1

MDPI and ACS Style

Rajora, A.K.; Ravishankar, D.; Zhang, H.; Rosenholm, J.M. Recent Advances and Impact of Chemotherapeutic and Antiangiogenic Nanoformulations for Combination Cancer Therapy. Pharmaceutics 2020, 12, 592. https://doi.org/10.3390/pharmaceutics12060592

AMA Style

Rajora AK, Ravishankar D, Zhang H, Rosenholm JM. Recent Advances and Impact of Chemotherapeutic and Antiangiogenic Nanoformulations for Combination Cancer Therapy. Pharmaceutics. 2020; 12(6):592. https://doi.org/10.3390/pharmaceutics12060592

Chicago/Turabian Style

Rajora, Amit K.; Ravishankar, Divyashree; Zhang, Hongbo; Rosenholm, Jessica M. 2020. "Recent Advances and Impact of Chemotherapeutic and Antiangiogenic Nanoformulations for Combination Cancer Therapy" Pharmaceutics 12, no. 6: 592. https://doi.org/10.3390/pharmaceutics12060592

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop